|Bid||0.7200 x 1400|
|Ask||0.7400 x 800|
|Day's range||0.7130 - 0.7599|
|52-week range||0.6680 - 6.0400|
|Beta (5Y monthly)||0.56|
|PE ratio (TTM)||N/A|
|Earnings date||14 Mar 2022 - 18 Mar 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||2.25|
CAMBRIDGE, Mass., January 10, 2022--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced the appointments of Minori Rosales, M.D., Ph.D. as Chief Development Officer as of January 24, 2022 and Stephanie Vigue as Director of Finance as of January 17, 2022.
The biotech, which concentrates on developing treatments for cancer, saw its share price dive by nearly 18% on the day. In August, the company's Biologics License Application (BLA) was rejected by the Food and Drug Administration (FDA). In its press release published just after the meeting, which Sesen Bio characterized as "productive," the company wrote that it now "believes it has greater clarity regarding the requirements for resubmission of the BLA and the trial design."
CAMBRIDGE, Mass., December 09, 2021--Sesen Bio (Nasdaq:SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced its anticipated regulatory path forward for Vicineum™ for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) following its Clinical Type A meeting with the US Food and Drug Administration (FDA), which occurred on December 8, 2021 (Clinical Type A Meeting).